A mathematical model for chemo-immunotherapy of cancer considering macrophages polarization and cytokine dynamics

preprint OA: closed
View at publisher

Abstract

Today, immunotherapy is one of the effective treatments along with chemotherapy. This is especially true in cancers, which cause the immune system’s failure. As a valuable tool, a mathematical model is developed in the form of ordinary differential equations (ODEs) to show the immune-tumor cells interaction. The macrophages polarization and cytokine dynamics are also regarded using standard pharmacokinetics-pharmacodynamics assumptions for better presenting the tumor-immune cells interaction. Its lack in researches of chemo-immunotherapy of cancer is what motivated us to come with an ODE model. The positivity of solutions, the equilibrium points, and their stabilities are studied. Moreover, the sensitivity of the final tumor population and response time to initial conditions and parameters’ values are investigated. Initial conditions of the adaptive immune system and the parameters related to tumor cells proliferation, tumor carrying capacity, and exponent of fractional tumor cell kill by CD8+T cells have more effect on the final tumor population and the response time of tumor growth. Then, numerical simulations for pulsed chemotherapy, pulsed immunotherapy, and chemo-immunotherapy are presented and compared. Three patients with different immune responses are regarded to show the effect of immune response on treatment strategy. Numerical simulations show the effectiveness of the immunotherapy along with chemotherapy for cancer treatment. Also, it is shown that the immune system’s strength has a remarkable role in cancer cure.

My notes (saved in your browser only)

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.

Source provenance

europepmc
last seen: 2026-05-19T01:45:01.086888+00:00